Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersNeurology Physician in Norman, OK
NPI: 1215969605Primary Practice Location
NORMAN REGIONAL
3300 Healthplex Pkwy, Norman, OK
Primary Employer
Oklahoma Medical Research Foundation
omrf.org
HQ Phone
Get M.D. Gabriel's Phone NumberMobile
Get M.D. Gabriel's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardOK State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 163 | 188 |
| 2 | 96413Infusion of chemotherapy into a vein up to 1 hour | 28 | 50 |
| 3 | 96415Infusion of chemotherapy into a vein | 28 | 53 |
| 4 | 96375Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | 25 | 55 |
| 5 | J2930Injection, methylprednisolone sodium succinate, up to 125 mg | 25 | 37 |
Autoantibodies identify primary Sjögren's syndrome in patients lacking serum IgG specific for Ro/SS-A and La/SS-B.
Authors: Judith James, R Scofield, Alan Baer
Publication Date: 2023-09
Authors: Myassar Zarif, Bianca Weinstock Guttman, Mark Gudesblatt, Samuel Hunter, Mahmoud Abdelrazek, Andrew Smith
Journal: Neuroimage Clin
Publication Date: 2024-04-27
Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis.
Authors: Ulrike Kaunzner, Anne Cross, Benjamin Greenberg, Jeffrey Gelfand, David Hafler, Simon Thebault, Christopher Lock, Lay Kodama, Carolina Ionete, Robert Fallis, Steven Yuen
Journal: JAMA Neurol
Publication Date: 2024-03-11
Lead Sponsor: Yale University
Collaborators: Genentech, Inc.
Intervention / Treatment: OTHER: Placebo, DRUG: Ocrelizumab
Lead Sponsor: EMD Serono Research & Development Institute, Inc.
Collaborators: Merck KGaA, Darmstadt, Germany
Intervention / Treatment: OTHER: Data Collection
Lead Sponsor: Johns Hopkins University
Collaborators: Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society
Intervention / Treatment: OTHER: Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, OTHER: Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq
